Anjuli Timmer

Dr. Timmer is the Vice President of Operations of Aardvark Therapeutics, Inc. Prior to joining Aardvark, she served as Preclinical and Clinical Program Director at NantKwest Inc. where she was involved in the research and development of targeted natural killer cell therapeutics. Previously, Dr. Timmer was a Senior Scientist and Project Manager at Tanabe Research Laboratories, a subsidiary of Mitsubishi Tanabe Pharmaceutical Corp. At Tanabe she worked on antibody generation, engineering, oncology, and immunology projects. Dr. Timmer has co-authored several patents and numerous publications throughout her career as a scientist. Dr. Timmer received her Ph.D. in Molecular Pathology from the University of California, San Diego and her B.S. in Biology from the University of New Hampshire.